These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 24627290

  • 1. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
    Shin D, Cho YM, Lee S, Lim KS, Kim JA, Ahn JY, Cho JY, Lee H, Jang IJ, Yu KS.
    Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
    Kim SH, Lee SH, Yim HJ.
    Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA.
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
    Lee SW, Park SI, Lee S, Chung JY, Yu KS.
    Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH, Jung E, Yoon MK, Kwon OH, Hwang DM, Kim DW, Kim J, Lee SM, Yim HJ.
    Eur J Pharmacol; 2016 Oct 05; 788():54-64. PubMed ID: 27298192
    [Abstract] [Full Text] [Related]

  • 9. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH, Lim HS, Jin SJ, Kim MJ, Kim YH, Sung HR, Choi HY, Bae KS.
    Clin Ther; 2012 May 05; 34(5):1182-94. PubMed ID: 22534255
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
    Choi HY, Noh YH, Kim YH, Kim MJ, Lee SH, Kim JA, Kim B, Lim HS, Bae KS.
    Int J Clin Pharmacol Ther; 2014 May 05; 52(5):381-91. PubMed ID: 24495314
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
    Choi HY, Kim YH, Kim MJ, Lee SH, Bang K, Han S, Lim HS, Bae KS.
    Drugs R D; 2014 Sep 05; 14(3):165-76. PubMed ID: 24962635
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
    Park SE, Lee BW, Kim JH, Lee WJ, Cho JH, Jung CH, Lee SH, Suh S, Hur GC, Kim SH, Jang YH, Park CY, STABLE Study Group.
    Diabetes Obes Metab; 2017 Jun 05; 19(6):892-896. PubMed ID: 28058753
    [Abstract] [Full Text] [Related]

  • 15. A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
    Jung CH, Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Gemigliptin Study 006 Group.
    Diabetes Obes Metab; 2018 Jun 05; 20(6):1535-1541. PubMed ID: 29436761
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
    Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, Cho JY, Yu KS.
    Drug Des Devel Ther; 2016 Jun 05; 10():2525-34. PubMed ID: 27570447
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M, Saji T, Mita S, Kulmatycki K, He YL, Furihata K, Sekiguchi K.
    Int J Clin Pharmacol Ther; 2013 Aug 05; 51(8):641-51. PubMed ID: 23782587
    [Abstract] [Full Text] [Related]

  • 18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun 05; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
    Jeong SI, Kim Y, Nah JJ, Huh W, Jang IJ, Hwang JG, Lee S.
    Br J Clin Pharmacol; 2023 Jun 05; 89(6):1780-1788. PubMed ID: 36496349
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
    Li J, Klemm K, O'Farrell AM, Guler HP, Cherrington JM, Schwartz S, Boyea T.
    Curr Med Res Opin; 2010 Aug 05; 26(8):2003-10. PubMed ID: 20583949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.